

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE FOR FORM 1449/PTO		ATTY. DOCKET NO.: DX0903K1	SERIAL NO.: 09/963,347
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		APPLICANT: Fernando Bazan et al.	
(USE AS MANY SHEETS AS NECESSARY)		EXAMINER NAME: Chernyshev, Olga N	FILING DATE: 09/25/2001
		ART UNIT: 1649	

Sheet 1 of 1

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

Examiner initials*	Cite no. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	<sup>1</sup> 2
/OC/	AA	VALENZONA <i>et al.</i> , "Exogenous Interleukin 7 as a Proliferative Stimulant of Early Precursor B Cells in Mouse Bone Marrow: Efficacy of IL-7 Injection, IL-7 Infusion and IL-7-Anti-IL-7 Antibody Complexes," <i>Cytokine</i> , Vol. 10, No. 6, pgs. 404-412, (June 1998)	
/OC/	AB	MIYAJI, <i>et al.</i> , "A Comparison of Proliferative Response to IL-7 and Expression of IL-7 Receptors in Intermediate TCR Cells of the Liver, Spleen, and Thymus," <i>Cellular Immunology</i> Vol. 169, Article 0106, pgs. 159-165, (1996)	
/OC/	AC	PEARSON, <i>et al.</i> , "Effective Protein Sequence Comparison," <i>Methods in Enzymology</i> , Vol. 266, pgs. 227-258 (1996)	
/OC/	AD	MOTT, <i>et al.</i> , "Four-helix Bundle growth factors and their receptors: protein-protein interactions," <i>Current Opinion in Structural Biology</i> , Vol. 5, No. 1, pgs. 114-121, (1995)	
/OC/	AE	WINKLER, <i>et al.</i> , "Interleukin-3 and Interleukin-7 Are Alternative Growth Factors for the Same B-Cell Precursors in the Mouse," <i>Blood</i> , Vol. 85, pgs. 2045-2051, (1995)	
/OC/	AF	AL-SHAMII, <i>et al.</i> , "A Role for Thymic Stromal Lymphopoietin in CD4+ T Cell Development," <i>The Journal of Experimental Medicine</i> , Vol. 200, No. 2, pgs. 159-168, (2004)	
/OC/	AG	COSENZA, <i>et al.</i> , "Disulfide Bond Assignment in Human Interleukin-7 by Matrix-assisted Laser Desorption/Ionization Mass Spectroscopy and Site-directed Cysteine to Serine Mutational Analysis," <i>The Journal of Biological Chemistry</i> , Vol. 272, No. 52, pgs. 32995-33000, (1997)	
/OC/	AH	KRUSE, <i>et al.</i> , "Two distinct functional sites of human interleukin 4 are identified by variants impaired in either receptor binding or receptor activation," <i>The EMBO Journal</i> , Vol. 12, No. 13, pgs. 5121-5129, (1993)	
/OC/	AI	KROEMER, <i>et al.</i> , "Prediction of the three-dimensional structure of human interleukin-7 by homology modeling," <i>Protein Engineering</i> , Vol. 9, No. 6, pgs. 493-498, (1996)	
/OC/	AJ	OSBORN, <i>et al.</i> , "Overexpression of murine TSLP impairs lymphopoiesis and myelopoiesis," <i>Blood</i> , Vol. 103, No. 3, pgs. 843-851, (2004)	
/OC/	AK	QUENTMEIER, <i>et al.</i> , "Cloning of human thymic stromal lymphopoietin (TSLP) and signaling mechanisms leading to proliferation," <i>Leukemia</i> Vol. 15, No. 8, pgs. 1286-1292, (2001)	

Examiner signature:  /Olga Chernyshev/	Date considered:  08/21/2007
--	------------------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*